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Genomic  instability  can initiate  cancer,  augment  progression,  and inﬂuence  the overall  prognosis  of  the
affected  patient.  Genomic  instability  arises  from  many  different  pathways,  such  as  telomere  damage,
centrosome  ampliﬁcation,  epigenetic  modiﬁcations,  and  DNA  damage  from  endogenous  and  exogenous
sources,  and  can  be perpetuating,  or limiting,  through  the  induction  of mutations  or  aneuploidy,  both
enabling  and  catastrophic.  Many  cancer  treatments  induce  DNA  damage  to  impair  cell  division on a
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Cancer prevention
DNA damage
Nutraceutical
global  scale  but  it is accepted  that  personalized  treatments,  those  that are  tailored  to  the  particular  patient
and type  of  cancer,  must  also  be developed.  In this  review,  we detail  the mechanisms  from  which  genomic
instability  arises  and  can  lead to cancer,  as  well  as  treatments  and  measures  that  prevent  genomic  insta-
bility or  take  advantage  of  the  cellular  defects  caused  by genomic  instability.  In particular,  we  identify  and
discuss  ﬁve  priority  targets  against  genomic  instability:  (1)  prevention  of  DNA  damage;  (2)  enhancement
of DNA  repair;  (3)  targeting  deﬁcient  DNA  repair;  (4)  impairing  centrosome  clustering;  and,  (5)  inhibition
of telomerase  activity.  Moreover,  we highlight  vitamin  D  and  B, selenium,  carotenoids,  PARP  inhibitors,
resveratrol,  and  isothiocyanates  as priority  approaches  against  genomic  instability.  The  prioritized  tar-
get  sites  and  approaches  were  cross  validated  to  identify  potential  synergistic  effects  on a number  of
important areas  of cancer  biology.
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. Cellular mechanisms that prevent or promote genomic
nstability
Genomic instability plays critical roles in both cancer initiation
nd progression. This instability can manifest itself genetically on
everal different levels, ranging from simple deoxyribonucleic acid
DNA) sequence changes to structural and numerical abnormali-
ies at the chromosomal level. This section will brieﬂy outline the
echanisms that maintain the stability of nuclear and mitochon-
rial DNA and how these mechanisms may  become corrupted in
ancer cells.
.1. Telomeres foster chromosomal stability and can inhibit or
romote malignant transformation
The chromosome stabilizing role of intact telomeres was  rec-
gnized as early as the 1930s from independent research by
cClintock [1] and Muller [2] and more recent work has further
trengthened the connection between telomere dysfunction and
hromosomal instability (CIN) [3,4]. Telomeres, which are located
t the ends of each chromosome, consist of approximately 5–10 kbp
f specialized, tandem repeat, noncoding DNA complexed with a
ariety of telomere associated proteins [5,6]. These elements create
 protective cap that prevents the recognition of the chromosomal
ermini as DNA double strand breaks (DSBs) and their consequent
berrant repair via nonhomologous end joining (NHEJ) or homol-
gous recombination (HR) [7–10]. Due to the inability of DNA
olymerase to fully replicate the ends of linear DNA molecules, in
he absence of compensatory mechanisms, telomeric DNA is lost
t the rate of approximately 100 base pairs (bp) per telomere per
ell division [11–17]. In normal somatic cells, this telomere erosion
s used by the cell to monitor its division history, with moderate
elomere shortening triggering either irreversible cell cycle arrest,
ermed replicative senescence, or apoptosis [18–21]. This block to
ontinued proliferation is thought to have evolved to prevent the
evelopment of cancer in long-lived organisms by restricting the
ncontrolled outgrowth of transformed cell clones, and also by pre-
enting further telomere erosion which would accompany such
bnormal growth and eventually destabilize the telomeres leading
o CIN [13,22].
A  current popular model for the involvement of telomere short-
ning in carcinogenesis posits that increasing numbers of cells
xperience telomere shortening as a person ages, which increases
he pool size of cells that are in danger of experiencing eventual
elomere dysfunction and prooncogenic CIN. In the vast majority of
uch cells, the senescence and apoptotic blocks are strictly enforced
23–28]. However, this process eventually fails in rare cells which
ontinue to replicate and eventually experience CIN due to crit-
cal telomere shortening [15,29–37]. Notably, such cells may  be
ore tolerant of rampant genomic instability due to their previous
brogation of the tumor suppressive telomere length checkpoints.
owever, if left unchecked, this instability will eventually reachhed  by Elsevier  Ltd.  This  is  an  open  access  article  under  the  CC  BY  license
(http://creativecommons.org/licenses/by/4.0/).
lethal levels in the transforming cells, thereby presenting a sec-
ond block to the development of cancer [37–40]. This escalating
telomere driven CIN creates a strong selective pressure for telo-
mere maintenance in incipient cancer cell populations; a problem
that is solved in one of two  ways: activation of telomerase or
alternative lengthening of telomeres (ALT). In the majority of
human cancers, the telomere speciﬁc reverse transcriptase telo-
merase, which is stringently repressed in normal somatic cells,
is activated, thereby restabilizing the telomeres, although can-
cer telomeres on average seem to remain very short [32,41–45].
Whereas most cancers use telomerase to maintain telomere length,
a signiﬁcant minority of cancers (typically non-carcinomas) utilize
ALT, a telomerase independent, homologous recombination based
mechanism [46–48]. This mode of telomere maintenance results in
extreme telomere length heterogeneity and, interestingly, better
patient survival compared to their telomerase positive counter-
parts in several tumor types [49–52]. These observations suggest
that cancer cells utilizing ALT may  have compromised their vital-
ity in exchange for the unlimited replicative potential conferred by
this telomere maintenance mechanism.
1.2. Centrosomes, the spindle assembly checkpoint, and
tumorigenesis
The centrosome is the primary microtubule organizing center
in dividing mammalian cells and is composed of a pair of centri-
oles surrounded by a cloud of proteins that promote microtubule
nucleation [53,54]. The centrosome is duplicated in a semicon-
servative fashion with one daughter centriole formed next to a
preexisting mother centriole, and this process only occurs once in
every cell cycle [53,55]. Centrosome ampliﬁcation, the presence of
greater than two centrosomes during mitosis, is a common char-
acteristic of most solid and hematological tumors that may  induce
multipolar mitoses, chromosome missegregation, and subsequent
genetic imbalances that promote tumorigenesis [54,56].
Centrosome ampliﬁcation may  be caused by diverse mecha-
nisms, including centrosome overduplication [53,57–59], de novo
assembly, [60–62] and mitotic failure downstream from mono- [63]
or multipolar division [64–69]. The end result of these structural
abnormalities is often cytokinesis failure, which can give rise to
tetraploid binucleated cells and genome instability downstream.
Over time, the net result is a small population of cells that harbor
the ability to manage extra centrosomes, which could account for
the accumulation of cancer cells with centrosome ampliﬁcation and
aneuploidy.
Catastrophic aneuploidy and nonviable daughter cells are a
possible tumor suppressive consequence for centrosome abnor-
malities [70]. However, cancer cells have developed mechanisms
that overcome this fate by clustering multiple centrosomes into
a “pseudobipolar” state [59,70–72]. Cancer cells may  utilize
this mechanism to dampen high level aneuploidy and extreme
CIN, leading to better prognostic outcomes [73,74]. Centrosome
in Can
c
i
p
G
c
a
t
t
q
p
a
v
m
c
c
B
o
a
s
t
c
f
m
o
m
w
c
c
s
a
r
i
o
i
o
a
c
t
w
c
p
a
a
s
m
p
o
s
i
p
c
i
c
m
l
i
p
1
ﬁL.R. Ferguson et al. / Seminars 
lustering in tumor cells is not completely understood, but it
s likely to rely on microtubule associated proteins and motor
roteins that bundle together microtubules and centrosomes [71].
iven that centrosome clustering may  be advantageous for cancer
ell survival, this process may  be an attractive and speciﬁc ther-
peutic target [71,75,76]. In theory, the induction of multipolarity
hrough declustering of supernumerary centrosomes will selec-
ively target cancer cells without affecting healthy cells [71,75–77].
Bipolar chromosome attachment during mitosis is ensured by a
uality control mechanism known as the spindle assembly check-
oint. The assembly checkpoint senses tension across kinetochores
s a measure of bipolar attachment of chromosomes, and pre-
ents the onset of anaphase in the presence of unattached and/or
isattached chromosomes [78]. Any failures to sense errors will
ompromise the checkpoint and, potentially, induce instability.
The assembly checkpoint relies upon kinase signaling to delay
ell cycle progression and correct attachment errors. Aurora kinase
, for example, detects misattached chromosomes [79,80] and
verexpression of the kinase is sufﬁcient to disrupt the checkpoint
nd promote tetraploidy [81]. Moreover, mutations or expres-
ion changes in other checkpoint gene products may  compromise
he checkpoint and favor tumorigenesis [82–85]. Lastly, oncogenic
ues, such as overexpression of Aurora kinase A, may  override a
unctioning checkpoint and enable cells to enter anaphase despite
isattached chromosomes [86]. Cancer cells may  take advantage
f the checkpoint for their own beneﬁt. For example, checkpoint
ediated delay provides time for centrosome clustering [71],
hich can be manipulated by disabling or restoring assembly
heckpoint function [77]. The ability to manipulate or hijack the
ell’s innate quality control mechanism may  act as a selection pres-
ure, and cancer cells that possess this ability may have a growth
dvantage over others.
Correlation between aberrant centrosome numbers and aber-
ant chromosome numbers dates back over 100 years [87], yet there
s still a debate whether supernumerary centrosomes are the cause
r the result of genomic instability, or vice versa [54]. One interest-
ng phenomenon that may  shed light on this debate is the presence
f a transient tetraploid state during tumorigenesis [88].
Tetraploidy arises after cytokinesis failure following prolonged
ctivation of the assembly checkpoint, regardless of the reason for
heckpoint activation [54]. Depending on the status of tumor pro-
ein 53 (TP53), a tumor suppressor, the aborted postmitotic cells
ill either undergo apoptosis after prolonged cell cycle arrest or
ontinue to cycle [56,89–92]. In p53 null cells, a postmitotic check-
oint is compromised, which enables the cell to progress through
 subsequent cell cycle with double the amount of centrosomes
nd genetic material [57,89]. Consequently, each subsequent divi-
ion for these tetraploid cells will be more error prone, generating
ore unstable and detrimental aneuploidy [88]. A TP53-dependent
ostmitotic checkpoint is frequently mutated during early stages
f tumorigenesis [88,90–92], which suggests that the tetraploid
tate serves as an intermediate for the aneuploid state observed
n cancer cells [88]. In patients with Barrett’s oesophagus, the
resence of tetraploid cells is detected before aneuploid cells and
orrelates with early loss of TP53 [93]. Tetraploid cells were also
solated from p53-/− mouse mammary epithelial cells, and these
ells formed tumors in nude mice and showed increased aberrant
itoses and genomic instability in culture [94]. Therefore, regard-
ess of how centrosome ampliﬁcation or genomic instability occurs
n this “chicken or egg” argument, it is clear that either event is
ositively enhanced by the other in promoting tumorigenesis..3. Epigenetic mechanisms contributing to genomic instability
A plethora of studies, including more recent genome-wide pro-
ling, have demonstrated that epigenetic changes direct differentcer Biology 35 (2015) S5–S24 S7
cellular phenotypes in both normal and cancer cells [95–97].
Epigenetics refer to all heritable changes that may  modify gene
expression without changing the primary DNA sequence, such as
DNA methylation and chromatin remodelling. Epigenetic modiﬁca-
tions are established during differentiation and are stably inherited
and maintained through multiple rounds of cell division. Epigenetic
processes that lead to genomic instability and ultimately malignant
transformation constitute heritable changes that modulate gene
expression and can also affect DNA repair dynamics [95–97].
DNA methylation consists of the addition of a methyl group at
the carbon 5 position of the cytosine pyrimidine ring or the num-
ber 6 nitrogen of the adenine purine ring [98,99]. Most cytosine
methylation occurs in the context of cytosine-phosphate-guanine
(CpG) dinucleotides, and occurs via a group of DNA methyl-
transferase enzymes resulting in silencing of gene transcription
[100,101]. Aberrant changes in DNA methylation were among the
ﬁrst events to be recognized in cancer [102]. Global hypometh-
ylation in repetitive sequences of the genome can occur early
during tumorigenesis and may  initially predispose premalignant
cells to repetitive sequence genomic instability [103]. Furthermore,
hypomethylation of the promoter of oncogenes can increase their
expression [104] and lead to genomic instability [105,106]. Simi-
larly, aberrant sequence speciﬁc hypermethylation in cancer cells
can lead to further genomic instability by the silencing of genes
involved in cell cycle regulation and DNA repair [107]. A prominent
example is the aberrant methylation of CpG islands in the promoter
regions of DNA mismatch repair (MMR)  genes that result in cancer
cells with a “mutator phenotype” [108,109].
In addition to DNA methylation, histone molecules that form
the primary protein component of chromatin also regulate genome
stability as well as gene transcription [110]. A number of post-
translational modiﬁcations such as acetylation, deacetylation,
methylation, phosphorylation and ubiquitination have been identi-
ﬁed that alter the function of histones [111]. Various combinations
of these posttranslational histone modiﬁcations have been hypoth-
esized to form a “histone code” that dictate distinct chromatin
structures that can affect genome stability pathways and tran-
scription [95,97,98,112]. Acetylation of the lysine residues at the
amino (N) terminus of histone proteins removes positive charges,
thereby reducing the afﬁnity between histones and DNA to facili-
tate access by ribonucleic acid (RNA) polymerase and transcription
factors to gene promoter regions [112]. Therefore, in most cases,
histone acetylation enhances transcription while histone deacety-
lation represses transcription. In addition, histone acetylation can
affect DNA repair by promoting histone dynamics that stimulate a
DNA damage response in response to ionizing radiation [113–118].
Similarly, histone ubiquitination can also modify DNA repair capac-
ity [119–123]. Brieﬂy, ubiquitinated histones can lead to chromatin
structures that are conducive to the assembly of nucleotide exci-
sion repair complexes on damaged DNA [124], as well as both
types of DSB repair pathways and cell cycle checkpoint factors
critical for the DNA damage response [119–126]. Monoubiquitina-
tion of histones H2A and H2B prevents chromatin compaction and
facilitates assembly of the repair machinery at the damaged sites
[126]. Polyubiquitination of histone H2A and H2AX is important
for the retention of repair proteins, such as TP53 binding protein
1 (53BP1) and breast cancer 1 (BRCA1), at damaged loci [120,127].
Finally, histone phosphorylation is an early event following DNA
damage and required for efﬁcient DNA repair. Upon introduction
of a DSB, hundreds of histone molecules become phosphorylated
within minutes at the chromatin ﬂanking the break site, thus pro-
viding a rapid and highly ampliﬁed detection system and a focus
for the accumulation of many other proteins involved in DNA repair
and chromatin remodelling [128]. These examples, and numerous
other observations, suggest that a vast array of epigenetic mecha-
nisms contribute to the genomic instability in cancer cells.
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.4. Mitochondrial DNA alteration in human cancers
Mitochondrial genetic reprogramming and energy balance
ithin cancer cells play a pivotal role in tumorigenesis and are
uly regarded as one of the hallmarks of human cancer [129]. In
927, Otto Warburg [130,131] identiﬁed mitochondrial dysfunc-
ion as a key component of tumorigenesis and numerous studies
ave since elaborated upon the role of mitochondrial DNA (mtDNA)
lterations in different human cancers [132].
Mitochondria are the key component of the oxidative phos-
horylation system to generate cellular adenosine triphosphate.
hey uniquely possess their own DNA and generate reactive oxygen
pecies (ROS) [132]. Most human cells contain hundreds of nearly
omoplasmic (identical) copies of mtDNA, which are maternally
nherited [132]. Compared to the nuclear DNA, the mutation rate
f mtDNA is nearly 10 times higher and alterations are much easier
o detect due to their high copy number in cancer cells.
A substantial number of studies identiﬁed somatic mtDNA
utations involving coding and noncoding mtDNA regions in var-
ous cancers [132–136]. Among the noncoding mtDNA mutations,
 poly C mononucleotide repeat (known as D310) was  frequently
ltered in numerous cancers and appeared to be a mutational hot
pot [132]. Notably, coding mtDNA mutations targeting respiratory
omplex I, III,  IV or V were frequent in a variety of human can-
ers [132–138]. Moreover, alteration of mtDNA copy number could
otentially be associated with mitochondrial dysfunction leading
o disease progression [132,133]. In recent studies, a correlation
etween mutations in mtDNA and epidermal growth factor receptor,
r prostate-speciﬁc antigen expression, was established in lung and
rostate cancer, respectively [134,135]. These results suggest cross
alk between mitochondria and nuclear genomes maintain tumor
rowth.
In order to understand their role, a number of studies introduced
tDNA mutations in cancer cells. Introduction of a mitochondrial
utant adenosine triphosphate 6 (ATP6) (complex V) or cyclooxy-
enase 1 (COXI) (complex IV) increased the growth of prostate
ancer cells [136,139] or induced cancer cell proliferation and
ltered reactive oxygen and nitrogen species [140], respectively.
n a bladder cancer study, introduction of a mutant mitochon-
ria encoded cytochrome B (CYTB) induced bladder cancer growth
nd invasion, accompanied with increased ROS, lactate produc-
ion and oxygen consumption [141]. Moreover, the ROS-producing
YTB mutant tumor cells efﬁciently killed normal splenic immune
ffector cells, which may  provide tumor cells with an immune eva-
ion mechanism [141]. In addition, mutant CYTB overexpression
n nontumorigenic bladder epithelial cells triggered an increased
itochondrial proliferation and inhibition of apoptosis [142]. As
hese mutations in mtDNA were detected in human patients, the
receding studies suggest a causative role for mtDNA alterations in
umorigenesis.
. Repair pathways responsible for genetic ﬁdelity and
umor suppression
DNA is replicated with extreme ﬁdelity in normal cells with a
utation rate of 10−10 per base pair per cell division. DNA dam-
ge typically occurs through the following: (1) exposure to agents
uch as ultraviolet irradiation, genotoxic chemicals, and ionizing
adiation; (2) spontaneous DNA damaging events, such as a basic
ite formation; and (3) failure in normal cellular DNA processing
nd replication events, such as stalled replication forks. These pro-
esses induce oxidation, alkylation, crosslinking, dimerization, and
trand breaks in DNA, which must be resolved. As such, repair of
his DNA damage is essential to preserving genome integrity and
reventing cancer.cer Biology 35 (2015) S5–S24
2.1. Excision repair pathways
Three excision repair pathways can repair single stranded DNA
damage: nucleotide excision repair (NER), base excision repair
(BER), and DNA mismatch repair (MMR).
2.2. Nucleotide excision repair
Fidelity of genetic information transmission depends on NER,
which serves to repair DNA damage caused by ultraviolet irradi-
ation, alkylating and oxidizing agents, or chemotherapeutic drugs
that form bulky, helix distorting adducts. Two  sub-pathways have
been identiﬁed. Global genome NER repairs damage in both strands
of the DNA regardless of whether the gene is being actively
transcribed [143–145]. Transcriptionally coupled NER, however,
repairs transcriptionally active genes [143–145]. The two  path-
ways are similar in that they use many of the same pathways, but
global genome NER uses xeroderma pigmentosum complementa-
tion group C (XPC)-RAD23 homolog B (HR23B) and DNA damage
binding protein 1 (DDB1)-DDB2/XPE proteins to recognize distort-
ions in the double helix while transcriptionally coupled NER occurs
at regions where RNA Polymerase II has stalled [146–150]. Genetic
polymorphisms of NER gene products associate with human dis-
eases, including xeroderma pigmentosum, which can lead to severe
cases of skin cancer.
2.3. Base excision repair
The BER pathway ﬁxes damaged DNA bases (reviewed in [151]).
These lesions are recognized and removed by speciﬁc DNA glycosyl-
ases, which cleave the glycosidic bond between the damaged base
and the sugar of the DNA backbone. In more complex lesions, prolif-
erating cell nuclear antigen (PCNA), ﬂap endonuclease 1 (FEN1), and
DNA polymerase (POL) , with or without POL/, act to repair the
lesion. This complex set of events in BER is facilitated by poly (ADP-
ribose) polymerase 1 (PARP1), which recruits proteins involved in
the DNA repair response, such as X-ray repair cross-complementing
protein (XRCC)1, DNA ligase, and DNA polymerase [152,153].
Because cells are constantly subjected to DNA damaging condi-
tions, the BER pathway is crucial to preserving genome integrity.
This is exempliﬁed by the embryonic lethality of mice that possess
knockouts of key components of this pathway [154–156]. A bial-
lelic germline defect within a DNA glycosylase, mutY Homology
(MUTYH), was initially found in families that had excess colorec-
tal tumors with somatic mutations in the adenomatous polyposis
coli gene [157]. A subsequent larger study revealed that bial-
lelic germline MUTYH defects conferred 93 fold excess risk of
colon cancer with penetrance by age 60 [158,159] and may also
confer increased risk for endometrial cancer [160]. Mutations in
another glycosylase, 8 Oxoguanine (OGG1), have been associated
with laryngeal cancers [161] while gastric cancers harbor inacti-
vating mutations in glycosylase nei endonuclease VIII-like 1 (NEIL1)
[162]. Taken together, these studies conﬁrm the importance of BER
in the suppression of carcinogenesis.
2.4. DNA mismatch repair
Some evidence suggests that proofreading activity of replicative
DNA polymerases and MMR  machinery act in series in mam-
malian cells [163–166]. MMR  targets could generally be classiﬁed
into base/base mispairs and large insertion–deletion loops. At
the forefront of error recognition, MutS protein homolog (Msh)
2 pairs with Msh6 or Msh3, to form MutS (Msh2/Msh6) and
MutS (Msh2/Msh3). Whereas the former is mostly responsible
for base/base mispairs, the latter targets large insertion–deletion
loops. To initiate the repair process, MutL homolog 1(Mlh1)/Pms2
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eterodimers (MutL homologues), in the presence of exonuclease1,
nteract with MutS complexes to create nicks in the 3′ and 5′ of
he nascent strand containing the mismatch. Following nick cre-
tion, enzymes required to repair the damage site are recruited
nd resynthesis of the DNA is carried out by POL/. As a nexus
or DNA damage sensing and cell death, MMR  machinery play an
mportant role in recognizing damaged DNA and relaying signals
ownstream to activate a G2/M cell cycle checkpoint.
.5. Double strand break repair and cancer predisposition
The DSB is the most lethal form of DNA damage, as it can
ead to signiﬁcant DNA damage by multiple genomic changes,
ncluding translocation formation, deletions, and ampliﬁcations,
esulting in heritable cellular genomic instability/damage that can
ead to malignancy [167–169]. DSBs are repaired by both HR
nd NHEJ repair pathways. NHEJ repair occurs throughout the
ell cycle, while HR prevails in S and G2 phase cells (reviewed,
167–169]). NHEJ repair joins broken DNA ends without identify-
ng DNA sequence homology and is therefore highly error prone
169]. HR repair is dependent upon DNA sequence homology and
herefore is relatively error free [168–170].
Errors in the NHEJ pathway may  generate inappropriate dicen-
ric chromosomes that are covalently joined (reviewed, [171,172]).
hese dicentric chromosomes may  break during anaphase, produc-
ng new dicentric chromosomes through further NHEJ [171,172].
his process is known as the breakage fusion bridge (BFB) cycle,
hich is important in telomere related genome instability [172].
amaged telomeres will be processed by NHEJ, unless the bro-
en ends are healed by a new telomere, and continuation of the
FB cycle can result in complex chromosomal rearrangements
hat include gene loss, gene ampliﬁcation and unbalanced translo-
ations [171,172]. BFB cycles are self-perpetuating and result in
enetic heterogeneity in a variety of cancers [173].
HR repair involves multiple gene products some of which are
nvolved in repair of stalled replication forks [170]. The DSB is rec-
gnized by a Mre11-Rad50-NBS1 complex which recruits many
ifferent proteins, including proteins with topoisomerase, endonu-
lease, and helicase activity. Eventually a “synaptic complex” is
ormed which allows homologous single strand DNA (ssDNA) to
nvade and anneal to complementary DNA. DNA polymerase then
lls in the ssDNA gap and the synaptic complex is resolved. Both
rossover and non-crossover products can be created by this pro-
ess [167–170]. Interestingly, loss or mutation of many of these
ene products is associated with speciﬁc cancer prone diseases.
BRCA1 and BRCA2 are key players in the HR repair pathway and
ct as tumor suppressors by maintaining genome stability. Link-
ge studies in families with early onset breast cancer detected the
resence of a breast cancer susceptibility gene, BRCA1 [174]. Subse-
uently, mutations in BRCA1 were conﬁrmed in families with early
nset breast and ovarian cancer [175–178]. Later, a novel locus,
ncoding BRCA2,  was discovered and linked to breast cancer sus-
eptibility [179–181]. In one meta-analysis, cumulative breast and
varian cancer risks for BRCA1 mutation carriers are 57 and 40%,
espectively, while, for carriers of BRCA2 mutations, these risks
re 49 and 18%, respectively [182]. Furthermore, hereditary BRCA
utations have been also linked to pancreatic, prostate, and colon
ancers [183]. Of interest, germline mutations in BRCA1 versus
RCA2 associate with different subtypes of breast cancer. BRCA1
ssociated cancers are of the more aggressive triple negative sub-
ype and appear at an earlier age than sporadic tumors. In contrast,
RCA2-associated tumors relate mostly with hormone receptor
ositive breast cancers.
Like BRCA1 and BRCA2, partner and localizer of BRCA1 (PALB2)
romotes genome integrity through its role in DSB repair. It binds
nd colocalizes with BRCA2 in the nucleus to stabilize BRCA2 focicer Biology 35 (2015) S5–S24 S9
and facilitate the intra S phase checkpoint and HR repair [184].
Germline mutations in PALB2 confer a 2–5 fold increase in breast
cancer risk [185,186] and germline mutations have been recently
found in African American breast cancer patients [187,188]. PALB2
mutations have also been observed in 1% of Chinese women with
early onset breast cancer [189]. Interestingly, exome sequencing
identiﬁed PALB2 as a pancreatic cancer susceptibility gene [190]
and PALB2 mutations have been found in patients with familial
pancreatic cancers [191,192].
Fanconi anemia (FA) is an autosomal recessive disorder char-
acterized by congenital defects, CIN, hypersensitivity to DNA
crosslinks, bone marrow failure, and predisposition to cancer
[193,194]. Fifteen FA or FA-like genes have been identiﬁed, all
of which are involved in coordinating DNA repair through the
FA/BRCA pathway. Interestingly, two of these genes are BRCA2
(FANCD1) and PALB2 (FANCN), thus revealing interplay between FA
and HR [195,196]. Patients with FA have increased susceptibility to
breast, ovarian, and oral cancers. Additionally, heterozygote carri-
ers of germline mutations in FA genes may  also harbor an increased
risk to develop cancer. Importantly, unlike the BRCA-associated
cancers, tumors from FA patients, or with acquired FA defects,
may  be hypersensitive to crosslinking agents such as cisplatin and
mitomycin C, and also are hypersensitive to radiation [197–199].
Finally, biallelic loss of ataxia telangiectasia mutated (ATM) results
in ataxia telangiectasia, a disease characterized by a roughly 1000
fold increased lymphoma incidence [200,201].
3. Therapeutic targeting of genomic instability
Current standard therapies for cancer often involve agents or
strategies that damage the DNA, which can also damage noncancer-
ous tissues. New treatments that target genomic instability (Fig. 1)
may  minimize these off target toxicities to normal tissues.
3.1. Targeting DNA repair pathways in cancer therapy
Drugs that target DNA repair proteins have shown preclinical
and/or clinical efﬁcacy in potentiating DNA damage (reviewed in
[202]). Synthetic lethality, whereby deﬁciencies in parallel path-
ways are only cytotoxic when both pathways are defective, is a
novel strategy that may  selectively target cancerous cells defec-
tive in DNA repair [203]. Synthetic lethality was illustrated in BRCA
deﬁcient cells, which exhibited profound sensitivity to inhibition
of PARP [204,205]. This was  due to conversion of unrepaired sin-
gle strand breaks into DSBs during DNA replication due to the
BRCA deﬁciency. Persistence of the unrepaired DSBs led to pro-
found cellular cytotoxicity. The potential efﬁcacy of PARP inhibitors
in patients with BRCA-associated cancers has been reported in
multiple clinical trials [206–211]. Perhaps more important is the
high therapeutic index of these compounds, since noncancerous
cells in this patient population still maintain one wild type allele
and thus remain HR proﬁcient. Natural products have also been
shown to act on PARP, such as isothiocyanates, which are found
in Brassica vegetables. Isothiocyanates stimulate the proteolytic
cleavage of PARP [212]. Recent work implicates vitamin D as a pos-
sible treatment mechanism to supplement PARP treatment [213].
BRCA1-deﬁcient cells bypass growth arrest by activating cathep-
sin L (CTSL)-mediated degradation of 53BP1. Vitamin D depletes or
inhibits CTSL leading to increased genomic instability and compro-
mised cancer cell proliferation after irradiation and treatment with
PARP inhibitors [213]. Selenocysteine can induce ROS formation,
which can lead to DSBs in cancer cells but not in normal human
ﬁbroblasts [214]. Thus, DSB repair deﬁcient cancers may  be sensi-
tive to treatment with selenium compounds.
In addition to defective DSB repair, inappropriate HR often
results in a signiﬁcant predisposition to cancer development
S10 L.R. Ferguson et al. / Seminars in Cancer Biology 35 (2015) S5–S24
Fig. 1. Genome stability is dependent on faithful DNA repair and chromosome segregation during cell division. During S phase, the centrosome and genomic material are
replicated concurrently, and replication errors are repaired prior to mitotic entry (1). During mitosis, equal segregation of chromosomes requires a bipolar mitotic spindle,
telomere preservation and the completion of the spindle assembly checkpoint. Ectopic ampliﬁcation of centrosomes (2), telomerase dysfunction (3) and failure of the spindle
assembly checkpoint (4) may result in aborted mitosis. Mitotic failure gives rise to a single tetraploid cell (4 N) instead of two diploid cells (2 N). This tetraploid cell can
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200,201]. Many human malignancies with HR deﬁciency show
ncreased sensitivity to chemotherapy agents that cause DSBs, such
s ionizing radiation, bleomycin, and cisplatin. Additionally, agents
hich inhibit DNA replication, such as bifunctional alkylating
gents and topoisomerase inhibitors, also preferentially inhibit
he growth of HR deﬁcient malignant cells [170,215,216]. There
as been intense interest in identifying HR deﬁciencies in human
umors and targeting these tumors with DSB-inducing chemother-
peutic agents. Since ∼25% of human malignancies show HR defects
170], targeted treatment could eventually play a signiﬁcant role
n chemotherapy. As tumors often overexpress speciﬁc proteins
nvolved in HR, this approach might also preferentially target tumor
ver normal tissue [170,215–217]. A major challenge in this area is
he efﬁcient and accurate identiﬁcation of HR deﬁciency in human
alignancies.
Some of the proteins that have been proposed as useful tar-
ets to inhibit HR include ATM, checkpoint kinase (CHK)1&2, ataxia
elangiectasia and Rad3 related (ATR), and the FA pathway proteins
170]. Many inhibitors that target these enzymes are either in pre-
linical development or in the early phases of clinical development
218,219]. Resveratrol may  activate sirtuin 1 (Sirt1) activity [220],
hich is a nicotinamide adenine dinucleotide-dependent deacety-
ase that is known to activate DNA repair. Studies in mice have
hown that Sirt1+/−; p53+/− mice develop tumors in many different
issue types but mice treated with resveratrol display a reduced
mount of tumorigenesis [221], indicating that resveratrol could act
o prevent and/or treat cancers in patients that have reduced Sirt1
unction. Although in early development, therapies that speciﬁcally
lter HR are a promising area of research and may  contribute to to induce apoptosis or senescence (4). Thus, genomic instability is propagated in
targeted chemotherapy regimens that are more personalized and
effective.
3.2. Targeting microsatellite instability
MMR  inactivation is associated with the lack of repair of repli-
cation errors leading to an increase in spontaneous mutation rate
[222]. A marker of defective MMR  is microsatellite instability (MSI),
or numerous alterations in the lengths of microsatellites [223,224].
Tumors displaying MSI  are said to exhibit a “mutator phenotype”,
with a dramatic predisposition to somatic mutations.
The critical role of MMR  pathways in tumorigenesis is exem-
pliﬁed by the fact that germline mutations in the genes involved
in MMR  predispose to cancer development [225]. In the case of
colorectal cancer (CRC), MMR  deﬁciency is estimated to be present
in 15 to 17% of all primary cancers, including both sporadic CRC
and Lynch syndrome (then called hereditary nonpolyposis colorec-
tal cancer), though through different mechanisms [223,226,227].
Lynch syndrome is characterized by inactivating germline muta-
tions to MSH2, MSH6, PMS2, or MLH1,  whereas MLH1  expression
is silenced due to biallelic hypermethylation in sporadic CRC
[228–232]. MLH1 methylation results from extensive aberrant pro-
moter methylation [233,234]. The 3′ end of the MLH1 promoter,
proximal to the start codon, is most commonly methylated [227].
Methylation of the 5′ end of the MLH1 promoter can also occur,
however, the methylation pattern must extends to the 3′ end to be
deleterious [227]. Loss of MLH1 expression increases with age and
protein expression is lost by ∼50% in patients who are 90 years or
older [235]. The exact mechanism(s) behind MLH1 silencing remain
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nknown, but may  result from abnormal methylation [236], struc-
ural chromatin changes that increase accessibility to promoter
egions [237], or genomic damage [238]. Tumors with mutations
n the MLH1 gene are rare, which suggests that hypermethylation
f the MLH1 promoter is an important event in neoplastic transfor-
ation in sporadic CRC [234].
The extent of MSI  in CRC has been classiﬁed as MSS
microsatellite–stable), MSI-H (with high level of instability), and
SI-L (with low level of instability) [239]. Classiﬁcation between
SI-H and MSI-L depends on which MSI  markers are present and
heir proportions [240]. These markers include mononucleotide
epeats, such as BAT25, BAT26, and BAT40, and the dinucleotide
epeats D5S346, D2S123, and D17S250 [241–244]. Dinucleotide
arkers are present in both MSI-H and MSI-L cancers, whereas
ononucleotide markers are speciﬁc for MSI-H cancers [241]. In
SI-H tumors, more than 30% of these markers are unstable, while
n MSH-L tumors, 10–40% of these markers are unstable, and MSS
umors demonstrate no unstable markers [241,245–248]. MSI-L
nd MSS  tumors are frequently grouped together due to similar-
ties in their clinical features and gross abnormalities [248]. MSI-H
s most prevalent in sporadic CRC, observed in 10–15% of all cases
240,248].
The predictive value of MMR  status as a marker of response to 5
uorouracil, irinotecan and other drugs is still controversial [249].
ecently, two  large retrospective analyses from several random-
zed trials conﬁrmed the detrimental effect of a 5 ﬂuorouracil-based
djuvant therapy in stage II colorectal patients [250], not applicable
o stage III patients [251]. These latter authors, however, reported
hat MSI  stage III tumors harboring genetic mutation in the MMR
enes seem to beneﬁt from the 5 ﬂuorouracil adjuvant therapy.
hese data imply that molecular differences within the MSI  sub-
roup inﬂuence the response to 5 ﬂuorouracil.
The CRC MSI  subgroup represents a cancer with a deﬁned molec-
lar etiology, a characterized mutational proﬁle and an established
enotype–phenotype relationship, which may  enable synthetic
ethal approaches that target MMR  deﬁciency. High through-
ut experiments revealed synthetic lethal interactions between
SH2 and POLB, between MLH1 and Polymerase G gene [252],
etween RAD54B and FEN1 [253,254], between MLH1/MSH2 and
TEN-induced putative kinase 1 gene [255], and the preferential
ffect of methotrexate in MMR  deﬁcient systems [256]. These syn-
hetic interactions may  induce or accumulate ROS [257,258]. A
hase II randomized clinical trial in MLH2-deﬁcient metastatic
RC (NTC00952016) is currently underway [256]. Combination
herapy with methotrexate and PARP inhibitors may  be effective
gainst tumors with MMR  mutations. Methotrexate elevates ROS
nd DSBs and the combination of MMR  mutation and PARP inhi-
ition may  attenuate repair and induce growth arrest or apoptosis
259–261].
.3. Targeting gene expression of cell cycle and DNA repair
omponents
RNA interference (RNAi) may  enable personalized antitumor
herapies. A number of RNAi-based studies have silenced genes
esponsible for tumor cell growth, metastasis, angiogenesis, and
hemoresistance [262]. For example, siRNA targeting of Cyclin E
uppressed tumor development [263]. Epigenetic regulation of
ene expression is an alternative approach. Resveratrol, a phy-
oalexin produced by plants such as the Japanese knotweed,
revents hypermethylation of the BRCA1 promoter [264], and may
e effective for triple negative or basal subtype breast cancers.
ther natural compounds, like genistein and lycopene, can alter
NA methylation of the glutathione S transferase p1 (GSTP1) tumor
uppressor gene [265].cer Biology 35 (2015) S5–S24 S11
3.4. Targeting centrosome abnormalities
Centrosome ampliﬁcation is an important process during early
stages of cancer development (see Section 1.2). Though the
mechanism(s) behind centrosome ampliﬁcation remain elusive,
TP53 negatively regulates centrosome ampliﬁcation through a
TP53-p21-CDK2 signaling loop [266,267]. Moreover, TP53 induces
apoptosis through transactivation of proapoptotic genes and
transrepression of antiapoptotic genes [268]. Thus, TP53 pro-
vides an interesting link between two  major cancer processes,
centrosome ampliﬁcation and apoptosis dysregulation [268]. In
one study, the loss of TP53, or treatment with 5 ﬂuorouracil,
promoted centrosome ampliﬁcation in HCT116 cells and those
cells with supernumerary centrosomes were more acutely sen-
sitive to resveratrol [268]. However, TP53 defective cancer cells
that resist 5 ﬂuorouracil treatment are prone to centrosome
ampliﬁcation and downstream genome instability [269]. The
presence of supernumerary centrosome can also be problem-
atic for cancer cells. Clustering excess centrosomes may  be a
necessary prosurvival pathway for cancer cells and thus an attrac-
tive target [70]. Griseofulvin, an antifungal drug that suppresses
proliferation in tumor cells without affecting non-transformed
cells, declusters centrosome, although the precise mechanisms
behind the drug’s action remain unknown [71]. In a similar
fashion, depletion of a kinesin-like motor protein can selec-
tively kill tumor cells with supernumerary centrosomes [77].
Finally, the PARP inhibitor PJ34 also declusters supernumerary
centrosomes without deleterious effects on spindle morphology,
centrosome integrity, mitosis, or cell viability in normal cells
[270].
4. Prevention of genomic instability and human cancer
There is no question that optimizing nutrient intake plays a sig-
niﬁcant role in stabilizing the genome. In recent years, an increasing
number of biomarkers of genome integrity, including telomere
length and mtDNA deletions, have been utilized in establishing
recommended daily intakes for nutrients [271]. In several cases,
such an approach has led to substantial changes in the levels of
various nutrients that populations had been previously advised to
consume. These ﬁndings highlight the need to better optimize an
individual’s diet to their personal genetic makeup, which in turn
has prompted the emergence of nutrigenomics, a new ﬁeld that
aims to determine how a particular genotype or expression pro-
ﬁle correlates to nutrient metabolism, absorption, etc. (reviewed
in [272,273]).
4.1. Vitamins–carotenoids
Since Peto et al. [274] concluded that the evidence pointed to
a cancer preventive role for  carotene, many placebo-controlled
carotenoid intervention trials have been carried out with disease
and mortality as outcomes. Early ﬁndings were that, in subjects
who were smokers and/or asbestos workers, there was  a signiﬁ-
cant increase in lung cancer incidence [275]. A recent meta-analysis
conﬁrmed that a signiﬁcant increase in mortality is associated with
vitamin A,  carotene or vitamin E supplements [276]. When deter-
mining the effects that dietary supplements and other compounds
have on cancer prevention, it is important to take into account
the different types of data: conventional intervention studies, ani-
mal  experiments, cell culture studies, or human intervention trials
based on biomarkers. This is important because of the nature of
each type of experiment and the information that can be obtained
from them.
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.1.1. Human biomarker trials with molecular endpoints
Human trials with carotenoids [277–286] were mostly cross
ectional or case control studies, with a few intervention trials. In
eneral, a negative correlation was seen between blood carotenoid
evels and various biomarkers of DNA damage, and intervention
rials tended to show a decrease in DNA damage or no effect.
.1.2. Animal experiments
Most animal experiments [287–300] involved treatment of
ats or ferrets with genotoxic agents during or after carotenoid
upplementation, and generally decreased levels of DNA dam-
ge were reported. Another study [301] looked at base oxidation
n leukocytes and oxidation products in urine, reporting a
arotenoid-induced decrease in the former (but no effect on urinary
iomarkers). There was a decrease in endogenous DNA oxidation
n liver of mice fed tomato paste (rich in lycopene) [302].
.1.3. Cell culture experiments
We  found eleven cell culture studies [287,303–312] with provi-
amin A carotenoids ( and  carotene,  cryptoxanthin, retinoic
cid, retinal and retinol), and eight with nonvitamin A carotenoids
lycopene, lutein, astaxanthin or zeaxanthin) [294,304,313–318].
xperiments in most cases involved cotreatment with DNA dam-
ging agent and carotenoid. Concentrations of carotenoid varied
idely, from less than 1–100 M.  Here we found a very clear
attern in the results, depending on the type of carotenoid and
he concentration: while the non-vitamin A carotenoids invariably
esulted in a decrease in DNA damage, the provitamin A carotenoids
t low concentrations either had no effect or decreased DNA dam-
ge, while at concentrations above about 5 M,  increases in damage
ere the norm. Potential prooxidant effects of carotenoids can
robably be ruled out as a cause of this DNA damage, since there is
o obvious reason why provitamin A carotenoids should be more
ikely to act as prooxidants. Instead, we should perhaps be look-
ng at downstream effects of vitamin A itself, on transcription, via
etinoic acid and retinoic acid receptors binding to retinoic acid
esponse elements present in the regulatory sequence of many
enes.
In a review of effects of carotenoids on DNA repair [319], we
ound relatively few reports. Cells from the spleen of rats sup-
lemented with carotenoids (plus nicotinamide and zinc) showed
ccelerated repair of DSBs induced by radiation, and lympho-
ytes from human subjects given the same supplement mix  were
aster at rejoining hydrogen peroxide induced breaks [184]. Mixed
arotenes plus  tocopherol as a supplement in humans had no
ffect on DNA repair [320]. DSB rejoining was faster in Molt 17 cells
n the presence of  carotene, lutein or  cryptoxanthin [321], and
n HeLa and Caco2 cells with  cryptoxanthin [306]; but no effect
as seen in lymphocytes incubated with  carotene or lycopene
322] or with vitamin A [311].
Lung cells from ferrets supplemented with  carotene were
ested for BER capacity with an in vitro comet-based assay, and
howed an increase in activity [323]. B cryptoxanthin enhanced
ER of 8 oxoguanine in HeLa and Caco2 cells [306], but no effect of
arotenoids was seen in Molt 17 cells [321] or lymphocytes [320].
The pattern that emerges from this survey of carotenoid effects
n DNA damage is that, in cell culture at least, while nonvitamin
 carotenoids tend to decrease damage (whether endogenous or
nduced), at whatever concentration, the provitamin A carotenoids
how a clear tendency to cause or increase damage at high concen-
rations. Whether this can account for the apparent harmful effects
f  carotene as seen in the human clinical trials is not possible to
nswer at present.
Glutathione is another important antioxidant that can improve
utcomes for patients with cancer and can help reduce treat-
ent toxicity. Some studies have shown that supplementation withcer Biology 35 (2015) S5–S24
glutathione can reduce the toxicity of chemotherapy agents such
as cisplatin and cyclophosphamide during treatment [324,325].
Interestingly, while the antioxidant properties of glutathione may
reduce treatment toxicity, the same properties can make tumor
cells resistant to chemotherapy when glutathione is present in
high levels in the cells [326,327]. A GSTP1 polymorphism (GSTP1
Ile105Val), which has a seven fold higher efﬁciency, has been linked
to a reduced survival rate in cancer patients further emphasizing
that while glutathione may  be able to reduce treatment toxicity, it
can potentially also confer an advantage to the tumor cells as well
[328,329].
An additional aspect that may  lead to conﬂicting results
regarding the efﬁcacy of antioxidants in cancer treatment is the
oxidative stress that tumor cells experience in their microenviron-
ment. Tumor cells have been shown to undergo the Warburg effect,
which is where they produce energy primarily through glycolysis
rather than through aerobic respiration ([131]; reviewed in [330]).
The production of lactate in tumor cells rather than pyruvate, an
antioxidant, increases the load of ROS and increases oxidative stress
in the cancer cells. Recent work has suggested that cancer cells
might be targeted by using 3 bromopyruvate, an inhibitor of the
glycolysis enzyme hexokinase II, to amplify the Warburg effect in
cells [331].
4.2. Other vitamins
A range of B vitamins, including niacin (vitamin B3), folate (vita-
min  B9), and vitamin B12, signiﬁcantly interact to maintain the
stability of both nuclear and mitochondrial genomes. For example,
a niacin deﬁciency, common in certain populations, impairs the
function of the PARP family of enzymes, identiﬁed above as criti-
cal to DNA repair. A folate deﬁciency, especially in the presence of
suboptimal levels of vitamin B6 and vitamin B12, may  have signiﬁ-
cant effects on the expression of chromosomal fragile sites, leading
to chromosome breaks, micronuclei and deletions of mtDNA. It
may  also lead to reduced telomere length. There are consider-
able interindividual differences in people’s capacity to absorb and
metabolize these vitamins, dependent upon genotype and epigeno-
type [332].
Vitamin C is considered an antioxidant, and is present at high
concentrations (mM)  in certain tissues such as the eye. Effects on
various markers of genome stability were shown to depend on indi-
vidual diet-derived vitamin C concentrations, and also on exposure
to xenobiotics or oxidative stress [333]. Vitamin D is also critical
in the maintenance of genome stability, possibly through protec-
tion against oxidative stress, chromosomal aberrations, telomere
shortening and inhibition of telomerase activity [334].
4.3. Minerals
While a number of minerals are typically considered as tox-
icants, there are several that are essential micronutrients, albeit
usually with a narrow window of efﬁcacy as compared with toxic-
ity. These include iron [335], selenium [336], and zinc [337].
Selenium provides a useful illustration of the complexities of
reaching agreement on optimal population levels. The population
as a whole shows a “U” shaped curve for functionality, where low
and high selenium levels both increase genomic instability. Optimal
levels of selenium may  protect against DNA or chromosome break-
age, chromosome gain or loss, damage to mtDNA, and detrimental
effects on telomere length and function. One example of how sele-
nium can function is by protecting genome stability through a
BRCA1-dependent mechanism [338]. When cells are supplemented
with selenium, there is reduced DNA breakage and the number of
aneuploid cells is reduced when compared to control cells. Unfor-
tunately, these optima differ among individuals and according to
L.R. Ferguson et al. / Seminars in Cancer Biology 35 (2015) S5–S24 S13
Table  1
Cross-validation for priority targets against genomic instability.
Other cancer hallmarks Priority targets for genomic instability
Prevent DNA
damage
Enhance DNA
repair
Target deﬁcient
DNA repair
Block
centrosome
clustering
Inhibit
telomerase
Sustained proliferative signaling 0 0 0 0 +
[432,433]
Tumor-promoting inﬂammation −
[434–436]
−
[434–436]
−
[434–436]
+
[437,438]
+
[439,440]
Evasion of anti-growth signaling +
[441,442]
+
[441–443]
+
[444]
+
[445,446]
+
[447]
Resistance to apoptosis ±
[448]
±
[448]
±
[448]
0 +
[449]
Replicative immortality +
[450,451]
0 0 +
[452]
n/a – same
target
Dysregulated metabolism ±
[453]
±
[453]
±
[453]
+
[454]
+
[455,456]
Immune system invasion +
[352]
+
[352]
+
[352]
0 0
Angiogenesis −
[457–461]
−
[457–461]
0 +
[462]
+
[463–465]
Tissue invasion and metastasis +
[466,467]
+
[466,467]
+
[466,467]
+
[468,469]
+
[470–474]
Tumor microenvironment + +
[475]
+
[476]
+
[437]
+
[477]
Priority targets that were not only relevant for genomic instability, but also relevant for other aspects of cancer’s biology (i.e., anticarcinogenic) were noted as having
c ction
a rocar
F ent t
t
m
s
4
d
t
m
o
e
i
D
i
t
o
a
o
l
P
i
d
[
d
s
a
t
a
d
g
m
t
(
d
s
somplementary effects (+). Those targets that were found to have procarcinogenic a
ctions  in other aspects of cancer biology were mixed (i.e., reports showing both p
inally, we  indicate (0) in instances where no literature support was found to docum
he form of selenium in the diet [336,339]. Various genetic poly-
orphisms have been shown to affect the uptake and utilization of
elenium among individuals.
.4. Other dietary factors
Diets high in plant-based foods have been associated with
ecreased cancer risks [340]. Lim and Song [341] discuss how cer-
ain dietary components, common in plant foods, can alter DNA
ethylation levels, affecting genome stability and transcription
f tumor suppressors and oncogenes. Much of the available data
xist for folate, since this is a well-recognized nutritional factor
n one-carbon metabolism, acting to supply the methyl units for
NA methylation. This has been shown to be especially important
n the maternal diet as a lack of folate can lead to hypomethyla-
ion of some genes in their offspring. One well studied example
f this is the Agouti mutation in mice, which affects coat color,
s well as making the offspring more susceptible to cancer and
besity [342,343]. The Agouti mutation has been shown to be a
ack of methylation at the promoter of the Agouti gene [344].
regnant mice that were fed bisphenol A had offspring that exhib-
ted hypomethylation of the Agouti gene but, by feeding them
ietary supplements of folate, methylation status was rescued
345]. This data demonstrates the importance of the maternal diet
uring development to outcomes even later in life for their off-
pring. In other systems, folate supplements during pregnancy have
lso been shown to be protective against neuroectodermal brain
umors [346].
Alcohol, various polyphenols, phytoestrogens and lycopene
lso have demonstrable effects. Indeed, there is compelling evi-
ence that a considerable range of plant polyphenols may  stabilize
enomic DNA, through various processes, including effects on DNA
ethylation [347]. Duthie [340] suggested that the evidence is par-
icularly strong for berry phytochemicals, speciﬁcally anthocyanins
a class of ﬂavonoids), which modulate various biomarkers of DNA
amage and carcinogenesis, in both in vitro and in vivo animal
tudies. However, evidence for cancer preventive effects in human
tudies is currently weak.s were noted as having contrary effects (−). In instances where reports on relevant
cinogenic potential and anticarcinogenic potential), the designation (±) was used.
he relevance of a target in a particular aspect of cancer’s biology.
Accumulating evidence shows that genome integrity is highly
sensitive to nutrient status, and that optimal levels may  differ
among individuals. Many investigations to date are limited by
considering only the effects of single nutrients, without looking
at the potential interactions among these, and of nutrients with
toxicants in the diet. Many currently available studies also suffer
from a failure to consider the effects of genetic susceptibility. In
subsequent work, it will be critical to consider modifying and inter-
active effects with deﬁciencies in nutrients required for effective
DNA damage response, and DNA repair.
Hyperglycemia and a high fat diet have been shown to be pos-
itively correlated with an increased risk of cancers, such as breast
and endometrial cancers. Hyperglycemic diets have been shown
to increase the levels of many signaling molecules [348]. Rats that
were fed high fat diets had an increased risk of breast cancer in
their progeny [349]. These results were similar to those seen when
mice are treated with estradiol. In addition to an increased risk
of developing cancer, hyperglycemia, diabetes, and obesity have
been linked to a worse prognosis. Advanced breast cancer patients
with high blood glucose levels had a lower rate of survival than
those with normal sugar levels [350] and obese adolescents with
pediatric acute lymphoblastic leukemia had a higher likelihood of
relapse than a normal cohort [351].
5. Complementary effects on the enabling characteristics
of cancer while targeting genomic instability
Treatments that are less cytotoxic but can also act on multiple
different cancers and pathways that contribute to cancer forma-
tion is an important goal (Table 1). Work focusing on the effects
of vitamin D, vitamin B, selenium, carotenoids, PARP inhibitors,
resveratrol, and isothiocyanates has shown promising results
(Table 2).
During cancer formation, genetic instability interacts with many
other pathways that are integral to the survival and proliferation of
the cancer cells, such as inﬂammation, immune system evasion, or
apoptosis resistance. Preventing and/or treating genomic instabil-
ity can cause tumor cells to lose: (1) their replicative immortality;
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Table 2
Cross-validation for priority approaches against genomic instability.
Other cancer hallmarks Priority approaches for genomic instability
Vitamin D Vitamin B Selenium Carotenoids PARP inhibitor Resveratrol Isothiocyanates
Sustained proliferative signaling +
[478]
±
[259,426]
±
[357,479]
+
[480–482]
+
[358,483,484]
+
[354,355]
+
[485,486]
Tumor-promoting inﬂammation +
[487,488]
+
[393,394]
−
[395–397]
+
[398,399]
+
[400,401]
+
[402,489]
+
[403,404]
Evasion of anti-growth signaling +
[490–492]
0 +
[493,494]
±
[366,495]
+
[358]
+
[496,497]
+
[360,361,364]
Resistance to apoptosis +
[380]
0 +
[378]
+
[377]
+
[498]
+
[382]
+
[379]
Replicative immortality +
[369,370,374]
0 +
[182]
+
[369,372,373]
+
[368,499]
+
[375,376]
+
[364,371]
Dysregulated metabolism 0 0 0 +
[500]
0 +
[268,501–508]
+
[364,383,509]
Immune system invasion +
[406]
0 0 +
[405]
0 +
[407,510–513]
0
Angiogenesis +
[514]
±
[408–410,412,414]
±
[411,413,415,417]
+
[416]
+
[418]
+
[515], [516]
+
[419]
Tissue invasion and metastasis +
[517]
+
[425,426]
+
[351,427,428]
+
[429,431,518]
+
[484]
+
[519]
+
[363,420,430]
Tumor microenvironment +
[520]
0 +
[395]
+
[521]
+
[476]
+
[522]
+
[523]
Approaches that are not only relevant for genomic instability, but also relevant for other aspects of cancer’s biology were noted as having complementary effects (+). Those
approaches that were found to have procarcinogenic actions were noted as having contrary effects (−). In instances where reports on relevant actions in other aspects of
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pproach in a particular aspect of cancer’s biology.
2) their ability to evade the immune system; and/or, (3) their abil-
ty to evade antigrowth signaling (Table 1). For example, in MSI-H
RCs, the immune response can be evaded by mutations in the
eoantigens caused by defects in DNA repair machinery [352]. In
his case, by preventing genomic instability, it could be possible to
inimize the mutations that lead to immune system evasion.
Sustained proliferative signaling is required for cancer cell
rowth and vitamin D and resveratrol are able to inhibit this
ignaling [353–355]. There are no known interactions for the other
ompounds, except selenium, which inhibits growth in some cases
hile inducing it in others [356,357]. In a related characteristic of
ancer cells, evasion of antigrowth signaling, all compounds are
ble to inhibit growth except vitamin B, which shows no relation-
hip, and carotenoids, which have mixed results [255,358–366].
imilarly, all of the compounds are able to prevent replicative
mmortality by impairing telomerase activity or inducing senes-
ence [364,367–376] and increasing cell death except for vitamin
, which has no known relationship to apoptosis [377–382]. Dys-
egulated metabolism also contributes to cancer cell growth and all
f the compounds had complementary effects on metabolic path-
ays except vitamin D and PARP inhibitors, which have no known
ink [268,338,364,383–386].
Cancer cells use inﬂammatory agents in the microenviron-
ent to promote their proliferation and survival. One important
nﬂammatory signaling molecule is nuclear factor kappa-light-
hain-enhancer of activated B cells (NFB), a transcription factor
hose aberrant regulation has been linked to cancer [387,388].
nﬂammatory signaling, including that of NFB, can be affected
y the diet. It has been shown that compounds found in crucifer-
us vegetables can reduce NFB signaling in pancreatic cancer cells
389]. Polyphenols have also been shown to suppress transcription
actors upstream of NFB [390]. Inﬂammation, in general, is also
nhibited by all of the compounds, except vitamin B [354,391–404],
hile only vitamin D, carotenoids, and resveratrol prevent the
umor cells from evading the immune system [405–407].
Tumors need specialized environments to grow and thrive in.
s the tumor grows, new blood vessels need to form to providestances where no literature support was  found to document the relevance of an
the cells with oxygen and all of the treatment options selected
are able to inhibit angiogenesis, except vitamin B and selenium,
both of which show mixed results [408–419]. Interestingly though,
in regards to other factors that contribute to the tumor microen-
vironment, all compounds are able to provide therapeutic value
[395,420–424].
Effective treatments to prevent tissue invasion and metastasis
are important as these stages of cancer are associated with poor
outcomes. It has been found that all of the targeted treatments
are able to inhibit/prevent these pathways except for resver-
atrol and PARP inhibitors, which have no known relationship
[363,420,421,425–431]. Further work and clinical trials will have
to be performed to understand the full beneﬁt of these compounds
in regards to cancer treatment.
6. Conclusion
Genomic instability plays a critical role in cancer initiation and
progression. The ﬁdelity of the genome is protected at every stage
of the cell cycle. In cancer, the presence of aneuploid or tetraploid
cells indicates the failure of one or many of these safety nets. The
resultant genomic heterogeneity may  offer the cancer “tissue” a
selection advantage against standard of care and emerging thera-
pies. Understanding these safety nets, and how they are bypassed
in cancer cells, may  highlight new and more speciﬁc mechanisms
for cancer prevention or therapeutic attack.
The therapeutic targeting of genomic instability may  dampen
other enabling characteristic of tumors cells, such as replicative
immortality, evasion of antigrowth signaling, and tumor promot-
ing inﬂammation. To this end, vitamins, minerals, and antioxidants,
such as vitamin D, vitamin B, selenium, and carotenoids, as well as
nutraceuticals, such as resveratrol, have shown remarkable plas-
ticity in elucidating antitumor responses. In addition to alleviating
genomic instability, these compounds are known to inhibit pro-
liferative signaling [353–355], attenuate oncogenic metabolism
[268,338,364,383–386], and block inﬂammation [354,391–404].
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owever, caution must be applied as certain antioxidants, such
 carotene, may  promote carcinogenic processes in a dose- and
ontext-dependent manner.
While mortality rates associated with heart disease and stroke
ave been reduced ∼70% in the last 50 years, mortality rates asso-
iated with cancer remain largely unchanged. This is likely due to
ur ability to manage the risk factors for heart disease and stroke
nd our inability to detect and prevent genomic instability and can-
er. However, diet and lifestyle are two of our great hopes in this
rea. In particular, antioxidants are critical for the prevention of
NA damage that enables cancer initiation and growth. Growing
vidence shows that vitamins, minerals, and other dietary factors
ave profound and protective effects against cancer cells, whether
hey are grown in the lab, in animals, or studied in human popu-
ations. A better understanding of the effects and synergy of these
ietary factors in the prevention and treatment of genomic insta-
ility is critical to the future reduction of mortality associated with
ancer.
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